Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced its
continued sponsorship of The William A. Devane Early Career
Investigator Award at the 33rd International Cannabinoid
Research Society (ICRS) Symposium in Toronto, Ontario,
Canada.
Artelo congratulates the 2023 recipient of The William A. Devane
Early Career Investigator Award Josée Guindon, Ph.D., Associate
Professor, Department of Pharmacology and Neurosciences, at Texas
Tech University Health Sciences Center. The title of Dr. Guindon’s
awardee lecture is “Sex Differences in Endocannabinoid Signaling
Pathways Involved in Chronic Pain and Cancer: Present and Insights
into the Future.” Immediately following Dr. Guindon’s lecture,
Professor Saoirse O’Sullivan, Vice President of Translational
Science at Artelo will present Dr. Guindon her award.
“We are extremely pleased to be an integral part of the annual
ICRS symposia as the sponsor of The William A. Devane Early Career
Investigator Award for the past five years," said Gregory Gorgas,
Chief Executive Officer of Artelo. The impact of The William A.
Devane Early Career Investigator Award for Artelo has been
two-fold, both supporting high quality research and establishing
productive, long-term professional interactions; 2016 winner
Professor Saoirse O'Sullivan now leads Artelo’s Translational
Science research, and 2017 awardee, Dr. Martin Kaczocha, Assistant
Professor in the Department of Anesthesiology, Department of
Biochemistry and Cell Biology at Stony Brook University, New York,
is a scientific collaborator with Artelo on Fatty Acid Binding
Protein inhibition. “We look forward to collaborating with
additional top tier researchers recognized at the ICRS as we
advance our novel product candidates,” continued Mr. Gorgas.
The 2023 ICRS symposia has been especially noteworthy for new
data from Artelo’s development programs as it included announcement
of preclinical research results demonstrating greater efficacy with
ART12.11, a patented CBD cocrystal composition, compared to CBD
alone, in established stress-induced models of anxiety. “In
addition to very encouraging ART12.11 evidence, we were also
pleased to present positive efficacy data from two animal models of
painful neuropathies with ART26.12, our most advanced potent
inhibitor of Fatty Acid Binding Protein 5, establishing further
evidence of the potential role that modulation of lipid-signaling
pathways may play in the development of non-opioid therapeutics for
pain,” added Mr. Gorgas.
About The William A. Devane Early Career Investigator
AwardFormerly known as the Young Investigator Award, The
William A. Devane Early Career Investigator Award is granted each
year at the International Cannabinoid Research Society’s annual
symposium. The Award is a unique opportunity to identify and
showcase researchers who have demonstrated dedication to
endocannabinoid system research. Recipients receive grant
compensation and are featured with a lecture during the annual
symposium of the ICRS.
About ART12.11ART12.11 is a proprietary
cocrystal composition of cannabidiol (CBD). The crystal structure
of CBD is known to exhibit solid polymorphism, or the ability to
manifest in different forms. Artelo’s patented cocrystal is a
single crystalline form and, as such, has advantages over other
compositions of CBD that exhibit solid polymorphism. Preclinical
studies of ART12.11 have exhibited superior pharmacokinetics
compared to other forms of CBD. With improved pharmaceutical
properties, including solubility and dissolution, Artelo believes a
more consistent and improved bioavailability profile may ultimately
lead to improved safety and efficacy, thus making ART12.11 a
preferred CBD pharmaceutical composition.
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing our lead molecule
for Chemotherapy-Induced Peripheral Neuropathy, additional
compound(s) from our extensive library of potent and selective
inhibitors of FABPs have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. The ICRS
Symposium is being held at the Marriott Downtown at CF Toronto
Eaton Centre, Toronto, Canada, from June 24-29, 2023. Interested
parties may follow @ICRS_Society on Twitter.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in the Company’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De May 2023 a May 2024